Drug Trial Radar · NCT06971523
A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies
Last checked: Nov 19, 2026Latest source record: May 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
224
Planned (sponsor's estimate)
Start
Dec 25, 2024
Primary completion
Dec 31, 2028
Study completion Jun 30, 2029
Sponsor
- Lead sponsor
- CytosinLab Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of Phase I of this study is to evaluate the safety and tolerability, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of CTS3497 in patients with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deficient solid tumors and lymphomas. The primary objective of Phase II of this study is to evaluate the efficacy of CTS3497 in patients with metastatic or locally advanced MTAP-deficient solid tumors and lymphomas.
Conditions
- Solid Tumor
- Lymphoma
Interventions
CTS3497Drug
CTS3497: Orally via capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase I: Number of Patients Who Experience a Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days after the first administration.
- Phase I: Number of Patients Who Experience a Treatment-emergent Adverse Event (TEAE)Time frame: Baseline through 28 days after the end of treatment, estimated up to 52 weeks.
- Phase II: Objective Response Rate (ORR)Time frame: up to 48 weeks.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.